Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: A randomized, placebo-controlled Phase 2 trial
In this first global clinical study of a nanobody in inflammatory arthritis, sonelokimab, an
IL-17A- and IL-17F-inhibiting nanobody demonstrated strong efficacy across multiple domains including high-hurdle composite joint and skin responses. McInnes et al. reported on the Phase 2, randomized, double-blind, PBO-controlled ARGO trial which evaluated the efficacy and safety of sonelokimab in patients with active PsA.
Sonelokimab delivered significant improvements in the signs and symptoms of PsA across a range of outcomes and domains. Sonelokimab was well tolerated, with a safety profile consistent with IL-17 inhibition. Phase 3 studies are actively recruiting at sites across Europe, North America, and Latin America to evaluate sonelokimab 60mg and 120mg in patients with active PsA: IZAR-1 (NCT06641076) and IZAR-2 (NCT06641089).
An independent educational project sponsored by MoonLake
Keywords:
